Results 11 to 20 of about 6,286 (187)
Filling the Gaps in Antagonist CCR5 Binding, a Retrospective and Perspective Analysis
Frontiers in Immunology, 2022 The large number of pathologies that position CCR5 as a central molecular determinant substantiates the studies aimed at understanding receptor-ligand interactions, as well as the development of compounds that efficiently block this receptor.
Yerkezhan Amerzhanova, Luca Vangelista
doaj +1 more source
The role of CCR5 in HIV-associated neurocognitive disorders
Heliyon, 2022 While combination antiretroviral therapy (cART) has successfully increased the lifespan of individuals infected with HIV, a significant portion of this population remains affected by HIV-associated neurocognitive disorder (HAND). C-C chemokine receptor 5
Cecile Riviere-Cazaux +3 more
doaj +1 more source
Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5
Biophysical Journal, 2023 Abstract By driving monocyte chemotaxis, the chemokine receptor CCR2 shapes inflammatory responses and the formation of tumor microenvironments. This makes it a promising target in inflammation and immuno-oncology; however, despite extensive efforts, there are no FDA-approved CCR2-targeting therapeutics.
John R.D. Dawson +10 more
openaire +3 more sources
mBio, 2021 Zika virus (ZIKV) is a neurovirulent flavivirus that uniquely causes fetal microcephaly, is sexually transmitted, and persists in patients for up to 6 months.
Megan C. Mladinich +4 more
doaj +1 more source
Annals of Hepatology, 2021 Introduction and objectives: Intrahepatic (I-CCA) and extrahepatic (E-CCA) cholangiocarcinoma (CCA) have different growth patterns and risks for tumor metastasis. Inhibition and/or activation of the chemokine receptor CCR subclasses have been reported to
Jiaqi Yang +3 more
doaj +1 more source
PLoS ONE, 2022 CC Chemokine receptor 5 (CCR5), a member of the Superfamily of G Protein-Coupled Receptors (GPCRs), is an important effector in multiple physiopathological processes such as inflammatory and infectious entities, including central nervous system ...
Guillermo Goode-Romero, Laura Dominguez
doaj +1 more source
Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy
Frontiers in Immunology, 2022 Globally, human immunodeficiency virus type 1 (HIV-1) infection is a major health burden for which successful therapeutic options are still being investigated.
Hager Mohamed +6 more
doaj +1 more source
The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis
Exploration of Medicine, 2020 Pooled prevalence of nonalcoholic fatty liver disease (NAFLD) globally is about 25%. Nonalcoholic steatohepatitis (NASH) with advanced fibrosis has been linked with substantial morbidity and mortality, without having to-date any licensed treatment.
Michael Doulberis +4 more
doaj +1 more source
Microbiology Spectrum, 2022 HIV-1 uses CD4 as a receptor and chemokine receptors CCR5 and/or CXCR4 as coreceptors. CCR5 antagonists are a class of antiretrovirals used to inhibit viral entry.
Yueqi Du +7 more
doaj +1 more source
CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy
Molecules, 2019 HIV entry in the host cell requires the interaction with the CD4 membrane receptor, and depends on the activation of one or both co-receptors CCR5 and CXCR4.
Fedora Grande +8 more
doaj +1 more source